Np031112 800mg    (DrugBank: -)

1 disease
告示番号疾患名(ページ内リンク)臨床試験数
5進行性核上性麻痺2

5. 進行性核上性麻痺 [臨床試験数:82,薬物数:107(DrugBank:36),標的遺伝子数:60,標的パスウェイ数:90
Searched query = "Progressive supranuclear palsy", "PSP"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 82 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2009-013097-40-ES
(EUCTR)
17/11/200929/07/2009Estudio doble-ciego, controlado con placebo, aleatorizado, de grupos paralelos, para evaluar la seguridad, tolerancia y eficacia de dos dosis orales diferentes de NP031112, un inhibidor de GSK3, versus placebo, como tratamiento de pacientes con Parálisis Supranuclear Progresiva leve o moderadaEstudio doble-ciego, controlado con placebo, aleatorizado, de grupos paralelos, para evaluar la seguridad, tolerancia y eficacia de dos dosis orales diferentes de NP031112, un inhibidor de GSK3, versus placebo, como tratamiento de pacientes con Parálisis Supranuclear Progresiva leve o moderada Parálisis Supranuclear Progresiva leve o moderada
MedDRA version: 9;Level: LLT;Classification code 10036813;Term: Progressive supranuclear palsy
MedDRA version: 9;Level: PT;Term: Progressive supranuclear palsy
Product Name: NP031112
Product Code: NP031112 600mg
Other descriptive name: 4-benzyl-2-naphtalen-1-yl-1,2,4-thiadiazolidine-3,5-dione
Product Name: NP031112
Product Code: NP031112 800mg
Other descriptive name: 4-benzyl-2-naphtalen-1-yl-1,2,4-thiadiazolidine-3,5-dione
Noscira S.A.NULLNot RecruitingFemale: yes
Male: yes
125Spain;Germany;United Kingdom
2EUCTR2009-013097-40-DE
(EUCTR)
06/11/200930/07/2009A double-blind, placebo-controlled, randomized, parallel-group study evaluating thesafety, tolerability and efficacy of two different oral doses of NP031112, a GSK-3inhibitor, versus placebo in the treatment of patients with mild to moderateProgressive Supranuclear Palsy. - TAUROSA double-blind, placebo-controlled, randomized, parallel-group study evaluating thesafety, tolerability and efficacy of two different oral doses of NP031112, a GSK-3inhibitor, versus placebo in the treatment of patients with mild to moderateProgressive Supranuclear Palsy. - TAUROS Mild to Moderate Progressive Supranuclear Palsy
MedDRA version: 12.0;Level: LLT;Classification code 10036813;Term: Progressive supranuclear palsy
MedDRA version: 12.0;Level: PT;Term: Progressive supranuclear palsy
Product Name: NP031112
Product Code: NP031112 600mg
Other descriptive name: 4-benzyl-2-naphtalen-1-yl-1,2,4-thiadiazolidine-3,5-dione
Product Name: NP031112
Product Code: NP031112 800mg
Other descriptive name: 4-benzyl-2-naphtalen-1-yl-1,2,4-thiadiazolidine-3,5-dione
Noscira S.A.NULLNot RecruitingFemale: yes
Male: yes
125United Kingdom;Spain;Germany